Clinical trial
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of…
NCT00048555 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00048555 |
|---|---|
| Title | Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma |
| Official title | A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination With Rituxan® for Patients With Relapsed or Refractory, Follicular Lymphoma |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | IDEC-114 |
| Enrollment | 90 |
| Start date | Nov 1, 2002 |
| Primary completion | Mar 1, 2004 |
| Completion | Nov 1, 2010 |
| First posted | Nov 5, 2002 |
| Last update posted | Sep 16, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: